To date, only one other study by Ben-Sheetrit et al. (2020) has reported on similar outcomes, revealing elevated risk for non-compliance with oral glucose tolerance test screening in pregnant individuals with depression as they under-utilized tests perceived to be for the wellbeing of the mother and over-utilized tests perceived to be for the wellbeing of the fetus (e.g., alpha-fetoprotein to detect neural tube defects) [13]. This evidence concerns the gene AFP and depressive symptom measurement.